Open AccessAntitumor Activity of ME2303, a Fluorine‐containing Anthracycline, against Human Tumors Implanted in Nude Mice
Author(s) -
Tsuruo Takashi,
Sato Shigeo,
Yusa Keisuke
Publication year - 1989
Publication title -
japanese journal of cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 0910-5050
DOI - 10.1111/j.1349-7006.1989.tb01697.x
Subject(s) - adenocarcinoma , nude mouse , human breast , medicine , anthracycline , medullary cavity , human lung , chemotherapy , lung , cancer research , cancer , breast cancer
A fluorine‐containing anthracyctine, ME2303, given intravenously once a week for 4 weeks at the maximum tolerated dose showed better therapeutic effects against 2 gastric, 3 lung and 2 human breast tumor xenografts than did adriamycin (ADM) at the maximum tolerated dose. Among the tumors, ME2303 showed a better effect against St‐40, a well‐differentiated human gastric adenocarcinoma, against which ADM showed only a marginal effect. Likewise, ME2303 was more effective against Lu‐24 human small cell carcinoma and MX‐1 human medullary tubular adenocarcinoma than ADM. Notably, the Lu‐24 tumor, developed in nude mice, disappeared after the treatment in 3 out of 6 mice. ME2303 would be an interesting compound for phase I and II clinical studies in the future